Alliance Pharma plc (AIM:APH)

Market Cap	328.66M
Revenue (ttm)	183.15M
Net Income (ttm)	-33.58M
Shares Out	540.57M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	13.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,315,414
Average Volume	4,013,760
Open	60.60
Previous Close	60.60
Day's Range	60.30 - 66.20
52-Week Range	24.55 - 66.20
Beta	0.73
RSI	64.27
Earnings Date	Mar 21, 2025

About Alliance Pharma

Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 292
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: APH

Financial Performance

In 2023, Alliance Pharma's revenue was 180.68 million, an increase of 7.92% compared to the previous year's 167.42 million. Losses were -33.14 million, 56.2% more than in 2022.